VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISH 2022 | Novel targets in CAR-T therapy for multiple myeloma: integrin beta-7 & CD98 heavy chain

Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, explains the rationale for targeting novel antigens for CAR-T therapy in multiple myeloma, including activated integrin beta-7 and a glycoform of the CD98 heavy chain. This interview took place at the 38th World Congress of the International Society of Hematology 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter